Get the Stockscreener App
128.91
0.53%
0.68
After Hours:
128.91
Neurocrine Biosciences Inc stock is traded at $128.91, with a volume of 1.40M.
It is up +0.53% in the last 24 hours and up +0.71% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$128.23
Open:
$126.4
24h Volume:
1.40M
Relative Volume:
1.24
Market Cap:
$12.76B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
43.70
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
-2.44%
1M Performance:
+0.71%
6M Performance:
-15.09%
1Y Performance:
-15.83%
1-Day Range:
$124.54
$129.09
1-Week Range:
$124.54
$137.44
52-Week Range:
$84.23
$157.40
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
128.91 | 12.72B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Biosciences Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
Neurocrine (NBIX) Q2 Revenue Jumps 17% - The Motley Fool
Neurocrine (NBIX) Q2 Revenue Jumps 17% - Nasdaq
The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts - 富途牛牛
Guggenheim raises Neurocrine Bio. stock price target on strong Ingrezza sales - Investing.com Canada
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Neurocrine Bio. price target raised to $145 from $140 at Mizuho - Investing.com Canada
Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Bio. stock price target raised by BMO Capital to $124 - Investing.com
Neurocrine refines INGREZZA net sales guidance to $2.5B-$2.55B while CRENESSITY surges, driving revenue growth and pipeline expansion - MSN
Neurocrine: Q2 Earnings Snapshot - CTPost
Strong Earnings and Pipeline Progress Could Be a Game Changer for Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences 2025 Q2 Earnings Strong Growth as Net Income Rises 65.4% - AInvest
Neurocrine Biosciences (NBIX): Navigating Pricing Pressures While Delivering Strong Sales Growth in Q2 2025 - AInvest
Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Schizophrenia Market Size 2034: Clinical Trials, EMA, PDMA, FDA - openPR.com
Neurocrine Biosciences' Strategic Momentum in Movement Disorder Therapies: A Deep Dive into INGREZZA's Sustained Growth and CRENESSITY's Emerging Potential - AInvest
Neurocrine Biosciences Q2 2025 Earnings Call: INGREZZA Sets New Sales Records, CRENESSITY Surges, and Revenue Growth Soars. - AInvest
Neurocrine Biosciences, Inc. 2025 Q2 Earnings and Strategic Momentum: A Deep Dive into Long-Term Growth Potential - AInvest
Earnings call transcript: Neurocrine Biosciences Q2 2025 earnings beat expectations - Investing.com Australia
Earnings call transcript: Neurocrine Biosciences Q2 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Neurocrine Biosciences' Q2 2025 Outperformance: A Case for Sustainable Growth and Premium Valuation - AInvest
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings - Yahoo Finance
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
Neurocrine Biosciences Inc Q2 Profit Increases, Beats Estimates - Nasdaq
Neurocrine Q2 2025 slides: revenue growth accelerates, pipeline expands By Investing.com - Investing.com South Africa
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results - PR Newswire
Published on: 2025-07-30 15:28:02 - metal.it
Neurocrine reports positive results from Crenessity trial - MSN
Published on: 2025-07-29 10:29:58 - metal.it
Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence - MSN
Endometriosis Market Predicted to See Upsurge Through 2034, - openPR.com
How Neurocrine Biosciences Inc. stock performs during market volatilityFree Membership Group - metal.it
Endometriosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma, Enteris BioPharma - Barchart.com
How volatile is Neurocrine Biosciences Inc. stock compared to the marketCapitalize on market momentum for profits - jammulinksnews.com
What makes Neurocrine Biosciences Inc. stock price move sharplyMarket-beating returns - jammulinksnews.com
Is Neurocrine Biosciences Inc. a growth stock or a value stockUnlock real-time trading signals for gains - jammulinksnews.com
Why is Neurocrine Biosciences Inc. stock attracting strong analyst attentionMaximize gains with proven stock analysis - jammulinksnews.com
Is Neurocrine Biosciences Inc. stock overvalued or undervaluedFree Stock Market Query - jammulinksnews.com
What institutional investors are buying Neurocrine Biosciences Inc. stockInvest confidently with daily market forecasts - jammulinksnews.com
How strong is Neurocrine Biosciences Inc. company’s balance sheetBuild a diversified portfolio for steady growth - jammulinksnews.com
Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating - MSN
Is Neurocrine Biosciences Inc. stock overhyped or has real potentialExponential wealth increase - jammulinksnews.com
10 Best Strong Buy Healthcare Stocks to Buy Now - Insider Monkey
Is Neurocrine Biosciences Inc. a good long term investmentRecord-breaking gains - Autocar Professional
Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.13%
1.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):